Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Goldman Sachs Maintains Neutral on Phathom Pharmaceuticals, Lowers Price Target to $9

Goldman Sachs analyst Paul Choi maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Neutral and lowers the price target from $15 to $9.
byBenzinga Newsdesk
August 3, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Goldman Sachs analyst Paul Choi maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Neutral and lowers the price target from $15 to $9.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts